A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Advenchen Laboratories, LLC, now recruiting.
Overview
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07392736 by Advenchen Laboratories, LLC, with 228 participants planned, started 2021-10-26 and due to reach its primary completion in 2029-11-07. Interventions recorded: AL8326 tablets and Toripalimab.
Similar pages
not linked directly; found by shared links- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Shares Advenchen Laboratories and the tag pipeline.
- TrialA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialIPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Shares Toripalimab and the tag pipeline.